[{"AccountsPayableCurrent_0_Q1_USD":997000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":48000.0,"MarketableSecuritiesCurrent_0_Q1_USD":106770000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_0_Q1_USD":31600000.0,"ProceedsFromSaleOfProductiveAssets_1_Q1_USD":24000.0,"OtherLiabilitiesNoncurrent_0_Q1_USD":6158000.0,"IncreaseDecreaseInAccountsAndOtherReceivables_1_Q1_USD":26000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":1275000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q1_USD":30690000.0,"OtherLiabilitiesCurrent_0_Q1_USD":7585000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_1_Q1_USD":78000000.0,"AccountsAndOtherReceivablesNetCurrent_0_Q1_USD":1828000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q1_USD":15.2,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-2000.0,"GainLossOnSaleOfPropertyPlantEquipment_1_Q1_USD":24000.0,"OtherLiabilities_0_Q1_USD":13743000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-16538000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":775000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-16540000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":1281173000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":1275000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_0_Q1_USD":8300000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":106779000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":15000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1_Q1_pure":0.012,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1_Q1_pure":0.97,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1_Q1_pure":0.98,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":685000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1_Q1_USD":0.0,"ProceedsFromStockPlans_1_Q1_USD":74000.0,"PaymentsToAcquireMarketableSecurities_1_Q1_USD":33970000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q1_USD":0.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":3088000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":1764000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":1372000.0,"InvestmentsAndCash_0_Q1_USD":176100000.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q1_USD":30700000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q1_USD":400000.0,"ContractWithCustomerLiability_0_Q1_USD":3153000.0,"ContractWithCustomerAssetNet_0_Q1_USD":0.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":25477000.0,"BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0_Q1_USD":107500000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1_1_Q1_USD":-483000.0,"AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":6000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1_Q1_pure":0.008,"OtherAssetsNoncurrent_0_Q1_USD":41000.0,"DeferredTaxLiabilities_0_Q1_USD":1840000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":567000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-18084000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":43487000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":74000.0,"LiabilitiesCurrent_0_Q1_USD":16977000.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":219065000.0,"Liabilities_0_Q1_USD":24899000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":2137000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":4121000.0,"EarningsPerShareBasicAndDiluted_1_Q1_USD":-0.42,"CostsAndExpenses_1_Q1_USD":17324000.0,"CommonStockValue_0_Q1_USD":40000.0,"CommonStockSharesOutstanding_0_Q1_shares":39614638.0,"CommonStockSharesIssued_0_Q1_shares":39614638.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":69313000.0,"AssetsCurrent_0_Q1_USD":181499000.0,"Assets_0_Q1_USD":219065000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":3046324.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":2587000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":3588000.0,"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0_Q1_USD":10600000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":3747000.0,"StockholdersEquity_0_Q1_USD":194166000.0,"BusinessCombinationContingentConsiderationLiability_0_Q1_USD":8750000.0,"InterestReceivable_0_Q1_USD":400000.0,"InterestAndOtherIncome_1_Q1_USD":101000.0,"IncreaseDecreaseInOtherOperatingLiabilities_1_Q1_USD":-578000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-1266000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1_Q1_pure":0.0,"ShareBasedCompensation_1_Q1_USD":1275000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":12720000.0,"PreferredStockValue_0_Q1_USD":null,"PreferredStockSharesOutstanding_0_Q1_shares":0.0,"PreferredStockSharesIssued_0_Q1_shares":0.0,"PreferredStockSharesAuthorized_0_Q1_shares":3000000.0,"PreferredStockParOrStatedValuePerShare_0_Q1_USD":0.01,"OperatingIncomeLoss_1_Q1_USD":-16639000.0,"CommonStockSharesAuthorized_0_Q1_shares":297000000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommitmentsAndContingencies_0_Q1_USD":null,"AccruedLiabilitiesCurrent_0_Q1_USD":7023000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q1_shares":39614000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1089634000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q1_USD":74000.0,"Ticker":"CLDX","CIK":"744218","name":"CELLDEX THERAPEUTICS, INC.","OfficialName":"Celldex Therapeutics Inc.","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1601609341.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20210506"}]